Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEOBiotechnology
Healthcare
$2.95 -0.94%
-$0.05 today
- Market cap
- $244.23M
- Beta
- 1.39
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$1.08
52W Low $3.60High $10.99
Volume 1.76M
Average 0.86M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$109.26M
FY 2025 · Annual
Net Income
-$99.96M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.66M | 654K | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 1.66M | 654K | 0 | 0 | 0 |
| Gross Margin | 100.0% | 100.0% | — | — | — |
| Research & Development | 45.12M | 49.16M | 53.13M | 74.09M | 63.8M |
| Selling, General & Admin | 7.17M | 12M | 15.38M | 31.68M | 45.46M |
| Operating Expenses | 52.29M | 61.16M | 68.51M | 105.77M | 109.26M |
| Depreciation & Amortization | 13K | 1.15M | 1.84M | 2M | 2.08M |
| EBITDA | (50.61M) | (58.04M) | (64.35M) | (96.19M) | (97.68M) |
| EBITDA Margin | -3054.3% | -8874.8% | — | — | — |
| Operating Income | (50.64M) | (60.51M) | (68.51M) | (105.77M) | (109.26M) |
| Operating Margin | -3055.9% | -9252.1% | — | — | — |
| Interest Income | 15K | 1.33M | 2.87M | 7.56M | 6.13M |
| Interest Expense | 0 | 91K | 205K | 114K | 206K |
| Other Income / Expenses | 15K | 1.23M | 2.12M | 7.43M | 9.3M |
| Income Before Tax | (50.62M) | (59.28M) | (66.39M) | (98.33M) | (99.96M) |
| Pre-Tax Margin | -3055.0% | -9063.8% | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (50.62M) | (59.28M) | (66.39M) | (98.33M) | (99.96M) |
| Net Margin | -3055.0% | -9063.8% | — | — | — |
| EPS (Basic) | (2.01) | (2.36) | (2.49) | (3.09) | (1.86) |
| EPS (Diluted) | (2.01) | (2.40) | (2.49) | (3.09) | (1.86) |
| 25.17M | 25.17M | 26.65M | 31.79M | 53.65M | |
| 25.17M | 25.17M | 26.65M | 31.79M | 53.65M |
LXEO Earnings Waterfall · TTM
NASDAQ:LXEO · Revenue to Net Income
Key Ratios
EPS$-1.45
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-5.4
P/S Ratio0.0
Analysis
$0 of revenue converted into -$87.5M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.45, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| EFFECT | EFFECT filing | Nov 4, 2026 | |
| S-3 | S-3 filing | Oct 29, 2026 | |
| SC 13G | SC 13G filing | Oct 13, 2026 |
How much revenue does LXEO generate?
Lexeo Therapeutics, Inc. Common Stock (LXEO) reported $0.00 of revenue in fiscal 2025.
Is LXEO profitable?
Lexeo Therapeutics, Inc. Common Stock (LXEO) reported -$99.96M of net income.
Continue the stock analysis
Jump to another research area for this company.